title: Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study.
abstract: The objectives of this study were to investigate the prevalence of infections with hepatotrophic viruses in an anti-human immunodeficiency virus (HIV)-positive population from Buenos Aires and to compare it among the main risk groups for HIV infection. Four hundred and eighty-four consecutive patients attending the HIV outpatients clinic were studied: 359 men and 125 women, median age 29 years (range 16-67 years); 35.5% had presented acquired immune deficiency syndrome (AIDS)-defining conditions. Two hundred and thirty-four patients were intravenous drug users (IVDU), 99 had homosexual and 142 heterosexual preference, seven had received blood transfusions and two had no risk factors. Hepatitis B surface antigen (HBsAg), and antibodies to hepatitis B core antigen (HBcAb) and to hepatitis C virus (anti-HCV) were investigated in all patients; antibodies to HBsAg (HBsAb) and IgG antibodies to hepatitis D virus (anti-HDV) in all HBcAb-positive patients; hepatitis B e antigen and antibodies to HBeAg (HBeAg) in all HBsAg-positive patients; IgG antibodies to hepatitis A virus (anti-HAV) in the first 307 patients; and IgG antibodies to hepatitis E virus (anti-HEV) in the first 91 patients. As control groups, contemporary voluntary blood donors were studied for prevalence of HAV, HBV, HCV and HEV. The percentages of HBcAb, HBsAg, anti-HCV and anti-HEV (58.5, 14.5, 58.5 and 6.6%, respectively) were significantly higher in anti-HIV-positive patients than in control groups (3.2, 0.5, 1.0 and 1.8%, respectively) (P = 0.000). The prevalence of HBcAb was significantly higher in IVDU (72.6%) than in heterosexuals (33.8%) (P = 0.0001) and in homosexuals (59.6%) (P = 0.0189). The percentage of HBsAg was significantly higher in IVDU (19.2%) than in heterosexuals (6.3%) (P = 0.0004). Anti-HCV was significantly higher in IVDU (92.3%) than in homosexuals (14.1%) and in heterosexuals (33.1%) (P = 0.000 in both cases). The prevalence of anti-HDV was relatively low (1.9%). There was no difference in the percentage of anti-HAV between HIV-positive and negative subjects. In conclusion, there is a high prevalence of HBV and HCV infections in HIV-positive patients from our area. Drug use is the main route of transmission, but prevalence of HCV in patients with, probably, sexually acquired HIV infection is also higher than in the control group. The increased prevalence of HEV infection in HIV-positive individuals is another provocative finding that warrants further study.
authors.affiliation: Dr Francisco Muñiz Hospital, Buenos Aires, Argentina.
authors.forename: H
authors.initials: H
authors.lastname: Fainboim
authors.forename: J
authors.initials: J
authors.lastname: González
authors.forename: E
authors.initials: E
authors.lastname: Fassio
authors.forename: A
authors.initials: A
authors.lastname: Martínez
authors.forename: L
authors.initials: L
authors.lastname: Otegui
authors.forename: M
authors.initials: M
authors.lastname: Eposto
authors.forename: P
authors.initials: P
authors.lastname: Cahn
authors.forename: R
authors.initials: R
authors.lastname: Marino
authors.forename: G
authors.initials: G
authors.lastname: Landeira
authors.forename: G
authors.initials: G
authors.lastname: Suaya
authors.forename: E
authors.initials: E
authors.lastname: Gancedo
authors.forename: R
authors.initials: R
authors.lastname: Castro
authors.forename: L
authors.initials: L
authors.lastname: Brajterman
authors.forename: H
authors.initials: H
authors.lastname: Laplumé
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001118:Argentina / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006508:Hepatitis Antibodies / Q000097:blood; D006525:Hepatitis, Viral, Human / Q000097:blood / Q000150:complications / Q000453:epidemiology* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D006508:Hepatitis Antibodies